'Rule Out No-Deal Brexit,' BIA Tells Government
Executive Summary
The BioIndustry Association wants the government to rule out a “no-deal” Brexit, saying it would be bad for patients and the life sciences sector.
You may also be interested in...
UK Govt Has ‘Made A Hash’ Of Managing Brexit For Life Sciences Sector
A recent debate in the House of Lords saw some fiery words exchanged over the government’s plans for the life science sector in the event of a no-deal Brexit, with accusations that they would produce a “clunky” regulatory system and put industry’s future “at grave risk.”
How The UK Regulatory System Would Work In A No-Deal Brexit – Part 2
In this second article on the regulations published by the government on how the UK would regulate medicines in a “no-deal” Brexit scenario, we look at what is being proposed for areas such as pediatric investigation plans, orphan medicines, pharmacovigilance, parallel trade, generics approvals, and good manufacturing and distribution practices.
UK Committee Urges Clarity On No-Deal Brexit Medicine Supplies
A parliamentary committee has called on the health department to provide more clarity as to how it plans to ensure continuity of medicine supplies in the event of a no-deal Brexit. At the same time, the government has produced a set of draft regulations allowing the UK MHRA to take over drug regulatory functions currently performed at EU level.